Avastin and Tarceva for Locally Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00043823|
Recruitment Status : Completed
First Posted : August 15, 2002
Last Update Posted : April 19, 2012
- (Phase I) To establish the maximum tolerated dose and dose-limiting toxicities of the combination of OSI-774 (Tarceva™) and rhuMAb VEGF (Avastin™) in patients with advanced Non-small-cell lung carcinoma (NSCLC).
- (Phase II) To assess response rate and tolerability of the regimen at the dose level established in the phase I portion of this study.
- (Phase I and II) To evaluate the pharmacokinetic interaction between the combination.
- (Phase I) To establish a phase II regimen of the OSI-774/ rhuMAb VEGF combination, for further study alone or in combination with cytotoxic chemotherapy.
|Condition or disease||Intervention/treatment||Phase|
|Lung Cancer||Drug: Avastin Drug: Tarceva||Phase 1 Phase 2|
Patients will be treated with oral Tarceva daily for 21 days each cycle. Patients will receive Avastin by IV on day 1 of each 21-day cycle. If a patient has no grade 3 or 4 toxicities after the 1st cycle, then the patient may continue the same doses of Tarceva and Avastin for another cycle. If the patient has response or stable disease after 6 weeks (2 cycles), the patient may continue on the same doses of Tarceva and Avastin. A patient may receive treatment on this study for up to one year, unless his or her disease progresses or side effects become too severe.
The starting dose is 100 mg daily of Tarceva and 7.5 mg/kg every 21 days of Avastin.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||41 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Safety and Efficacy of Recombinant Humanized Monoclonal Anti-VEGF Antibody rhuMAb VEGF and EGFR Tyrosine Kinase Inhibitor OSI-774 for Locally Advanced or Metastatic Non-Squamous Cell NSCLC in Patients Who Have Been Previously Treated|
|Study Start Date :||August 2002|
|Actual Primary Completion Date :||May 2006|
|Actual Study Completion Date :||May 2006|
Experimental: Avastin + Tarceva
Combination Therapy (Avastin + Tarceva) = Avastin IV Day 1 of each 21-day cycle + oral Tarceva daily.
7.5 mg/kg By Vein on Day 1 of Every 21 Day Cycle
Other Names:Drug: Tarceva
100 mg By Mouth Daily for 3 Weeks
- Maximum Tolerated Dose (MTD) of Tarceva in combination with Avastin [ Time Frame: After each 21 day cycle ]
- Response in Patients With NSCLC Receiving Combination Avastin and Tarceva [ Time Frame: 6 weeks (2 cycles) ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00043823
|United States, Tennessee|
|Vanderbilt-Ingram Cancer Center|
|Nashville, Tennessee, United States, 37232|
|United States, Texas|
|University of Texas M.D. Anderson Cancer Center|
|Houston, Texas, United States, 77030|
|Principal Investigator:||Roy S. Herbst, MD, PhD||M.D. Anderson Cancer Center|